234 related articles for article (PubMed ID: 37455272)
1. Incorporation of a Toll-like receptor 2/6 agonist potentiates mRNA vaccines against cancer and infectious diseases.
Gu Y; Yang J; He C; Zhao T; Lu R; Liu J; Mo X; Wen F; Shi H
Signal Transduct Target Ther; 2023 Jul; 8(1):273. PubMed ID: 37455272
[TBL] [Abstract][Full Text] [Related]
2. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.
Fotin-Mleczek M; Duchardt KM; Lorenz C; Pfeiffer R; Ojkić-Zrna S; Probst J; Kallen KJ
J Immunother; 2011 Jan; 34(1):1-15. PubMed ID: 21150709
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
J Virol; 2017 May; 91(9):. PubMed ID: 28228587
[TBL] [Abstract][Full Text] [Related]
4. Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity.
Kowalczyk A; Doener F; Zanzinger K; Noth J; Baumhof P; Fotin-Mleczek M; Heidenreich R
Vaccine; 2016 Jul; 34(33):3882-93. PubMed ID: 27269061
[TBL] [Abstract][Full Text] [Related]
5. An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.
Khalil SM; Tonkin DR; Snead AT; Parks GD; Johnston RE; White LJ
J Virol; 2014 Aug; 88(16):9182-96. PubMed ID: 24899195
[TBL] [Abstract][Full Text] [Related]
6. Spleen-selective co-delivery of mRNA and TLR4 agonist-loaded LNPs for synergistic immunostimulation and Th1 immune responses.
Pan L; Zhang L; Deng W; Lou J; Gao X; Lou X; Liu Y; Yao X; Sheng Y; Yan Y; Ni C; Wang M; Tian C; Wang F; Qin Z
J Control Release; 2023 May; 357():133-148. PubMed ID: 36972863
[TBL] [Abstract][Full Text] [Related]
7. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
[TBL] [Abstract][Full Text] [Related]
8. Antigen epitope-TLR7/8a conjugate as self-assembled carrier-free nanovaccine for personalized immunotherapy.
Song H; Su Q; Shi W; Huang P; Zhang C; Zhang C; Liu Q; Wang W
Acta Biomater; 2022 Mar; 141():398-407. PubMed ID: 35007785
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release.
Ilyinskii PO; Roy CJ; O'Neil CP; Browning EA; Pittet LA; Altreuter DH; Alexis F; Tonti E; Shi J; Basto PA; Iannacone M; Radovic-Moreno AF; Langer RS; Farokhzad OC; von Andrian UH; Johnston LP; Kishimoto TK
Vaccine; 2014 May; 32(24):2882-95. PubMed ID: 24593999
[TBL] [Abstract][Full Text] [Related]
10. Induction of innate immune signatures following polyepitope protein-glycoprotein B-TLR4&9 agonist immunization generates multifunctional CMV-specific cellular and humoral immunity.
Dasari V; Smith C; Schuessler A; Zhong J; Khanna R
Hum Vaccin Immunother; 2014; 10(4):1064-77. PubMed ID: 24463331
[TBL] [Abstract][Full Text] [Related]
11. Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses.
Dowling DJ; Scott EA; Scheid A; Bergelson I; Joshi S; Pietrasanta C; Brightman S; Sanchez-Schmitz G; Van Haren SD; Ninković J; Kats D; Guiducci C; de Titta A; Bonner DK; Hirosue S; Swartz MA; Hubbell JA; Levy O
J Allergy Clin Immunol; 2017 Nov; 140(5):1339-1350. PubMed ID: 28343701
[TBL] [Abstract][Full Text] [Related]
12. mRNAs encoding self-DNA reactive cGAS enhance the immunogenicity of lipid nanoparticle vaccines.
Zhivaki D; Gosselin EA; Sengupta D; Concepcion H; Arinze C; Chow J; Nikiforov A; Komoroski V; MacFarlane C; Sullivan C; Kagan JC
mBio; 2023 Nov; 14(6):e0250623. PubMed ID: 37937842
[TBL] [Abstract][Full Text] [Related]
13. Synergistic effect of dual targeting vaccine adjuvant with aminated β-glucan and CpG-oligodeoxynucleotides for both humoral and cellular immune responses.
Jin JW; Tang SQ; Rong MZ; Zhang MQ
Acta Biomater; 2018 Sep; 78():211-223. PubMed ID: 30098441
[TBL] [Abstract][Full Text] [Related]
14. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B
J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002
[TBL] [Abstract][Full Text] [Related]
15. A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice.
Laczkó D; Hogan MJ; Toulmin SA; Hicks P; Lederer K; Gaudette BT; Castaño D; Amanat F; Muramatsu H; Oguin TH; Ojha A; Zhang L; Mu Z; Parks R; Manzoni TB; Roper B; Strohmeier S; Tombácz I; Arwood L; Nachbagauer R; Karikó K; Greenhouse J; Pessaint L; Porto M; Putman-Taylor T; Strasbaugh A; Campbell TA; Lin PJC; Tam YK; Sempowski GD; Farzan M; Choe H; Saunders KO; Haynes BF; Andersen H; Eisenlohr LC; Weissman D; Krammer F; Bates P; Allman D; Locci M; Pardi N
Immunity; 2020 Oct; 53(4):724-732.e7. PubMed ID: 32783919
[TBL] [Abstract][Full Text] [Related]
16. S-540956, a CpG Oligonucleotide Annealed to a Complementary Strand With an Amphiphilic Chain Unit, Acts as a Potent Cancer Vaccine Adjuvant by Targeting Draining Lymph Nodes.
Nakagawa T; Tanino T; Onishi M; Tofukuji S; Kanazawa T; Ishioka Y; Itoh T; Kugimiya A; Katayama K; Yamamoto T; Nagira M; Ishii KJ
Front Immunol; 2021; 12():803090. PubMed ID: 35003132
[TBL] [Abstract][Full Text] [Related]
17. A-910823, a squalene-based emulsion adjuvant, induces T follicular helper cells and humoral immune responses
Yoshioka Y; Kobiyama K; Hayashi T; Onishi M; Yanagida Y; Nakagawa T; Hashimoto M; Nishinaka A; Hirose J; Asaoka Y; Tajiri M; Hayata A; Ishida S; Omoto S; Nagira M; Ishii KJ
Front Immunol; 2023; 14():1116238. PubMed ID: 36891311
[TBL] [Abstract][Full Text] [Related]
18. Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants.
Ali OA; Verbeke C; Johnson C; Sands RW; Lewin SA; White D; Doherty E; Dranoff G; Mooney DJ
Cancer Res; 2014 Mar; 74(6):1670-81. PubMed ID: 24480625
[TBL] [Abstract][Full Text] [Related]
19. Combination Adjuvants Enhance Recombinant Protein Vaccine Protection against Fungal Infection.
Wüthrich M; Dobson HE; Ledesma Taira C; Okaa UJ; Dos Santos Dias L; Isidoro-Ayza M; Petrovsky N; Klein BS
mBio; 2021 Aug; 12(4):e0201821. PubMed ID: 34399628
[TBL] [Abstract][Full Text] [Related]
20. Toll-like Receptor-4 (TLR4) Agonist-Based Intranasal Nanovaccine Delivery System for Inducing Systemic and Mucosal Immunity.
Bakkari MA; Valiveti CK; Kaushik RS; Tummala H
Mol Pharm; 2021 Jun; 18(6):2233-2241. PubMed ID: 34010002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
